(Q46917813)

26 December 2017

title

ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study (English)

1 reference

26 December 2017

1 reference

2

Edzard Schwedhelm

0 references

author name string

Rainer H Böger

1

1 reference

26 December 2017

Edzard Schwedhelm

2

1 reference

26 December 2017

Renke Maas

3

1 reference

26 December 2017

Sabine Quispe-Bravo

4

1 reference

26 December 2017

Cord Skamira

5

1 reference

26 December 2017

publication date

1 July 2005

1 reference

26 December 2017

published in

Vascular Medicine

1 reference

26 December 2017

volume

10 Suppl 1

1 reference

26 December 2017

page(s)

S97-102

1 reference

26 December 2017

Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Oxidative stress and diabetic vascular complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Evidence for a relationship between oxidative stress and insulin action in non-insulin-dependent (type II) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Oxidative stress measurement by in vivo electron spin resonance spectroscopy in rats with streptozotocin-induced diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Treatment with irbesartan or atenolol improves endothelial function in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Clinical Pharmacokinetics of Antioxidants and Their Impact on Systemic Oxidative Stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Divergence in plasmatic and urinary isoprostane levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Handling of commercially available enzyme immunoassays for 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha, iPF2alpha-III, 15-F2t-IsoP) in clinical research and science: considerations from the analytical and review point of view

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Blood pressure- and pulse pressure-lowering effects, trough:peak ratio and smoothness index of telmisartan compared with lisinopril.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM608OA

10.1191/1358863X05VM608OA

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017